Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79

Haematologica. 2017 Jul;102(7):e275-e277. doi: 10.3324/haematol.2016.161893. Epub 2017 Mar 24.

Authors

Andrew L Deng¹, Yu Ri Kim^{1

2}, Emily A Lichtenstein¹, Owen A O'Connor¹, Changchun Deng³

Affiliations

¹ Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
² Department of Internal Medicine, Yonsei University, Seoul, Korea.
³ Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA [email protected].

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
CD79 Antigens / genetics*
Female
Humans
Immunophenotyping
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics*
Mutation*
Myeloid Differentiation Factor 88 / genetics*
Piperidines
Positron Emission Tomography Computed Tomography
Pyrazoles / administration & dosage
Pyrimidines / administration & dosage
Recurrence
Retreatment
Treatment Outcome

Substances

CD79 Antigens
Myeloid Differentiation Factor 88
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine